By the PharmaTradz BD Team. Published October 2026.
Small-molecule drugs are relatively small chemical compounds, usually made by chemical synthesis, that can often be taken as tablets: think of paracetamol, metformin or atorvastatin. Biologics are large, complex molecules, mostly proteins such as insulin, vaccines and monoclonal antibodies, produced in living cells and usually given by injection. The difference is not just one of size. It changes how the medicine is made, tested, stored, copied and regulated, and it shapes almost every sourcing decision a buyer makes.
Side by side
| Small molecule | Biologic | |
|---|---|---|
| Size | Typically under about 1,000 daltons | Thousands to hundreds of thousands of daltons; an antibody is around 150,000 |
| How it is made | Chemical synthesis, step by step, with a defined structure | Living cells (bacteria, yeast or mammalian cells), followed by purification |
| Structure | Fully characterised and identical in every batch | Complex, with natural variation; the process largely defines the product |
| Typical route | Oral tablets and capsules, as well as injections and topicals | Mostly injection or infusion |
| Storage | Usually room temperature | Usually refrigerated, sometimes frozen |
| Copies | Generics, shown to be bioequivalent | Biosimilars, shown to be highly similar through extensive comparability studies |
| Manufacturing | Many API and formulation plants worldwide | Fewer, more specialised and capital-intensive facilities |
Generics versus biosimilars
A generic small-molecule medicine contains the same active substance as the original (some markets accept a different salt or ester with supporting data), so registration rests mainly on showing pharmaceutical quality and bioequivalence. A biologic cannot be copied exactly, because small changes in the cells or the process can change the product. A biosimilar therefore has to be shown to be highly similar to its reference product, with no clinically meaningful differences, through extensive analytical comparison and, often, clinical data. That takes longer, costs far more and requires different expertise, which is why there are fewer biosimilar suppliers than generic suppliers for any given molecule.
Regulators also differ on biosimilars. The EU has run a well-established biosimilar pathway for many years, the US has its own route with an additional "interchangeable" designation, and many emerging markets have adopted WHO guidance or their own rules. A biosimilar approved in one market is not automatically accepted in another.
Why biologics cost more to make and to copy
Making a biologic starts with developing a stable cell line that produces the protein reliably. The cells are then grown in large bioreactors under tightly controlled conditions, and the protein is separated from everything else the cells produce through a series of purification steps. Every stage must be validated, because the process itself defines the product. Facilities are expensive to build and run, and many biologics must be kept cold throughout distribution.
Developing a biosimilar repeats much of this work and adds a long programme of analytical comparisons with the reference product, often followed by clinical studies. That is why biosimilars are usually discounted less steeply than small-molecule generics, and why their arrival in a market still makes a large difference to access and to public budgets.
In between: peptides, conjugates and complex generics
Not everything fits neatly. Peptides such as semaglutide or teriparatide sit between the two worlds and may be made by synthesis or by biotechnology. Antibody-drug conjugates join a biologic antibody to a small-molecule drug. Products such as liposomal injections or inhaled medicines are small molecules in complex delivery systems and are often called complex generics. Each brings its own regulatory questions, so ask early how the destination regulator classifies the product.
What this means when you source
For small molecules, the questions are about the API source, the salt and form, the dosage form and the dossier. Our explainers on APIs and Drug Master Files cover them.
For biologics, add the cold chain from factory to patient, the comparability data behind a biosimilar, the reference product it was compared with, and whether that reference is accepted by your regulator. Our cold-chain logistics service and our guide to European contract manufacturers for biologics are useful starting points.
For the vocabulary of the manufacturing chain, see drug substance versus drug product, which also explains how the two terms apply to biologics.
More explainers
Related terms buyers ask about: immediate, extended, delayed and controlled release, batch versus lot numbers, fixed-dose combinations (FDCs) and what an excipient is. For supplier documents, see what a DMF is and how to read a Certificate of Analysis.
How PharmaTradz can help
Whether you need a small-molecule generic or a biosimilar, tell us the product, the market and the documents your regulator expects. We match you with manufacturers who can supply it and share their approvals and cold-chain arrangements before you commit. Send us an RFQ to get started.
Frequently Asked Questions(FAQs)
What is the difference between a small molecule and a biologic?
A small molecule is a relatively small chemical compound, usually made by synthesis and often taken as a tablet. A biologic is a large, complex molecule, usually a protein, made in living cells and mostly given by injection.
Is insulin a biologic?
Yes. Modern insulins are proteins produced in living cells using recombinant DNA technology, so they are regulated as biologics, and copies are approved as biosimilars rather than generics.
What is the difference between a generic and a biosimilar?
A generic contains the same active substance as the original and is shown to be bioequivalent. A biosimilar is highly similar to its reference biologic, with no clinically meaningful differences, shown through extensive comparability studies.
Why do most biologics need refrigeration?
Proteins can lose their structure and activity when exposed to heat, freezing or agitation, so most biologics must be kept in a controlled cold chain from manufacture to use.
Are peptides small molecules or biologics?
They sit in between. Peptides can be made by chemical synthesis or by biotechnology, and regulators classify them according to their size and manufacturing route.
